
Jan 9 (Reuters) -
AIRNEXIS THERAPEUTICS LAUNCHES WITH $200M SERIES A TO ADVANCE PHASE 2 DUAL PDE3/4 INHIBITOR AN01 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
AIRNEXIS THERAPEUTICS: OVER-SUBSCRIBED SERIES A WAS LED BY FRAZIER LIFE SCIENCES
Further company coverage: [ ]